YM BioSciences Inc. (YMI)

[surf1944]

1:50AM YM BioSciences reports Phase I/II data for JAK inhibitor CYT387 in myelofibrosis (YMI) 1.62 : Co reports updated results from the 166 patient Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The highlights include: -- 68% durable 12-week transfusion independence response rate with a maximal duration of response approaching three years and ongoing.

The percentage of patients requiring transfusions decreased substantially, from 44% at baseline to below 10% at week 40 of treatment.
37% durable spleen response per IWG-MRT with a maximal duration of response of nearly 2.5 years and ongoing.
The majority of subjects achieved a complete resolution or marked improvement of common constitutional symptoms.
The majority of adverse events were Grade 1.